ANDA 211432, held by Amneal. Succinylcholine Chloride.
As of Nov 16, 2026, ANDA 211432 (Succinylcholine Chloride), held by Amneal, was first approved by FDA on Nov 16, 2018, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Succinylcholine chloride injection is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 16, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Succinylcholine Chloride20MG/ML · injectable;injection | Succinylcholine Chloride | Discontinued |
| Jul 28, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| Apr 20, 2022 | Supplement 9Labeling · Standard review | Approved | None posted |
| Feb 24, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 16, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters